JP Morgan Chase
VRNA

JP Morgan Chase’s Verona Pharma VRNA Stock Holding History

JP Morgan Chase’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-40,400
Closed -$3.82M – 7749
2025
Q2 		$3.82M Buy
40,400
+13,200
+49% +$977K ﹤0.01% 3394
2025
Q1 		$1.73M Buy
+27,200
New +$1.63M ﹤0.01% 3984
2023
Q3 		– Sell
-198,000
Closed -$4.19M – 7759
2023
Q2 		$4.19M Buy
+198,000
New +$4.22M ﹤0.01% 3010

Other funds holding VRNA

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

JP Morgan Chase's VRNA Position: Q4 2025 in Review

JP Morgan Chase sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 1,414,770 shares — an estimated $151M sold.

JP Morgan Chase first reported a position in VRNA in Q4 2020 and held it in 15 quarters. The position peaked at $151M in Q3 2025. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.

  • JP Morgan Chase reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
  • JP Morgan Chase sold 1,414,770 Verona Pharma shares in Q4 2025, an estimated $151M.
  • JP Morgan Chase first reported a position in Verona Pharma in Q4 2020 and held it in 15 quarters.
  • JP Morgan Chase's Verona Pharma position peaked at $151M in Q3 2025.
  • 1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.

Based on JP Morgan Chase's 13F filing for Q4 2025, filed 11 Feb 2026.